Loading
Ovarian Cancer Diagnosis and Treatment / Advanced Breast Cancer Therapies · Journal article
Journal of Gynecologic Oncology · August 7, 2026
Reinforces what was already believed, rather than introducing something new.
This multicenter Japanese real-world cohort of 413 patients confirms that olaparib maintenance after platinum-sensitive first-relapsed ovarian cancer is well-tolerated and effective, with Grade ≥3 adverse events in 41.6% (anemia most common at 28.8%), median PFS of 12 months, and median OS of 39 months. Secondary hematologic malignancies remain a surveillance concern despite acceptable overall tolerability.
Multicenter, nationwide historical cohort study. Japanese patients with platinum-sensitive first-relapsed ovarian cancer who received olaparib maintenance therapy after platinum-based chemotherapy.. Intervention: Olaparib maintenance therapy after platinum-based chemotherapy. n = 413. 43 sites across Japan.
Grade ≥3 adverse events occurred in 41.6% (anemia 28.8%, myelodysplastic syndrome 1.0%, no acute myeloid leukemia) Median PFS was 12 months (95% CI=9.9-13) with 24-month PFS rate of 31.7% Median OS was 39 months (95% CI=33-45) with 24-month OS rate of 70.1%
Study does not report Grade 1-2 adverse events separately; toxicity burden may be underestimated. Grade ≥3 adverse events occurred in 41.6% (anemia 28.8%, myelodysplastic syndrome 1.0%, no acute myeloid leukemia)
These findings support olaparib maintenance as an acceptable real-world treatment option in Japanese clinical practice, confirming efficacy from trials. However, clinicians should counsel patients on Grade ≥3 toxicity risk (~42%), monitor for secondary hematologic malignancies, and note that median survival remains limited (39 months overall).
Real-world cohort study confirms safety and effectiveness of olaparib maintenance in Japanese patients with platinum-sensitive relapsed ovarian cancer, consistent with trial evidence but without comparative control arm.
As stated by the source record.
Quoted from the source exactly as published.
These findings support olaparib maintenance as an acceptable real-world treatment option in Japanese clinical practice, confirming efficacy from trials. However, clinicians should counsel patients on Grade ≥3 toxicity risk (~42%), monitor for secondary hematologic malignancies, and note that median survival remains limited (39 months overall).
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
OBJECTIVE: The primary objective of the study was to evaluate the safety and effectiveness of olaparib maintenance therapy in Japanese patients with platinum-sensitive first-relapsed ovarian cancer. The secondary objective was to survey the treatment given after the olaparib maintenance therapy. METHODS: The JGOG3026 study was a nationwide, multicenter historical cohort study across 43 sites. Patients receiving olaparib maintenance therapy after platinum-based chemotherapy between January 2018 and July 2020 were included as modified intention-to-treat (mITT) 1. Those who received any post-olaparib therapy were extracted as mITT2. The primary endpoint was Grade ≥3 adverse event; secondary endpoints included progression-free survival (PFS), the time to first subsequent therapy (TFST), progression-free survival to the second progression (PFS2), and overall survival (OS). RESULTS: In the mITT1 (n=413), any Grade ≥3 adverse events occurred in 41.6%; anemia was the most common (28.8%). Myelodysplastic syndrome occurred in 1.0% and no acute myeloid leukemia was observed during a mean follow-up of 34.1 months. The 24-month PFS and OS rates were 31.7% and 70.1%, respectively. Median PFS and OS were 12 months (95% confidence interval [CI]=9.9-13) and 39 months (95% CI=33-45). The 24-month TFST and PFS2 rates were 33.3% and 34.3%. In the mITT2 (n=284), chemotherapy after olaparib therapy was used in 97.2%, with an overall response rate of 22.5%. CONCLUSION: Olaparib maintenance therapy showed acceptable safety and effectiveness in Japanese clinical practice. Monitoring for secondary hematologic malignancies is needed after the start of olaparib maintenance therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.